Pharmaceutical

CPHI Europe: Overcoming the unique challenges with high-concentration mAbs

High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.

Oct 12, 2024 - 04:00
CPHI Europe: Overcoming the unique challenges with high-concentration mAbs
High-concentration monoclonal antibodies (mAbs) are gaining prominence given the compliance and cost advantages.
Read the original article

Tags:

Previous Article

CPHI Europe: Targeting supply chain bottlenecks key for cell and gene therapies

Next Article

The medical device sector’s surging regulatory burden: how are suppliers coping?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Menarini signs agreement for Astellas’s rheumatoid arthritis therapy

Menarini signs agreement for Astellas’s rheumatoid arth...

Sep 13, 2023

CHMP recommends full marketing approval for Gilead Sciences’ Hepcludex

CHMP recommends full marketing approval for Gilead Scie...

May 6, 2023

STAT+: Biden administration makes opening offers in Medicare drug price negotiations

STAT+: Biden administration makes opening offers in Med...

Feb 1, 2024